Literature DB >> 10654114

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.

J Ichikawa1, H Y Meltzer.   

Abstract

Clozapine, iloperidone, quetiapine, olanzapine, risperidone and ziprasidone represent the new generation of antipsychotic drugs, successors to the typical antipsychotic drugs such as chlorpromazine and haloperidol. The first group of agents are usually referred to as atypical antispychotics because they produce significantly fewer extrapyramidal symptoms than do the typical neuroleptics at clinically equivalent doses. These drugs also show advantages in treating positive symptoms, especially in patients whose positive symptoms fail to respond to the typical antipsychotic drugs. They also have advantages for treating negative symptoms, cognitive dysfunction and mood stabilization. There are variations to the extent to which the atypical antipsychotics show these advantages with regard to efficacy and side effects. The mechanism of action of these drugs is a matter of keen interest. We review here the evidence that some, or all, of these advantages are related to their actions at serotonin and dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654114     DOI: 10.1007/pl00014190

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  17 in total

1.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

2.  Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.

Authors:  Catharine A Winstanley; Yogita Chudasama; Jeffrey W Dalley; David E H Theobald; Jeffrey C Glennon; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-02       Impact factor: 4.530

3.  Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit.

Authors:  Alessandro Gozzi; Valerio Crestan; Giuliano Turrini; Marcel Clemens; Angelo Bifone
Journal:  Psychopharmacology (Berl)       Date:  2010-01-29       Impact factor: 4.530

4.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

Review 5.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

Review 6.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Mei Huang; Adam J Prus; Jin Dai; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

8.  Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.

Authors:  Julia Pinsonneault; Wolfgang Sadée
Journal:  AAPS PharmSci       Date:  2003-11-05

9.  DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia.

Authors:  Philip R Szeszko; Colin A Hodgkinson; Delbert G Robinson; Pamela Derosse; Robert M Bilder; Todd Lencz; Katherine E Burdick; Barbara Napolitano; Julia D Betensky; John M Kane; David Goldman; Anil K Malhotra
Journal:  Biol Psychol       Date:  2007-11-01       Impact factor: 3.251

10.  Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

Authors:  Alice Egerton; Rabia Ahmad; Ella Hirani; Paul M Grasby
Journal:  Psychopharmacology (Berl)       Date:  2008-07-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.